FDA Removes Black-Box Warnings From Three More Menopause Patches 2026

The FDA has removed black-box warnings from three more menopause patches, marking another controversial step in the agency's approach to menopause hormone therapy (MHT). The decision, announced Friday, means these treatments will no longer carry the agency's most serious safety alerts about cardiovascular disease, breast cancer, and dementia.

This move follows the removal of similar warnings from six menopause treatments in February. What makes this latest action notable is that the FDA did not convene an advisory committee and offered few details on the scientific basis for the decision during a press briefing.

Why the FDA's Decision Raises Concerns

The lack of transparency has drawn criticism from health experts. When journalists asked for the evidence behind the decision, officials said it could be provided later. That response has left some researchers uneasy.

"I have been concerned by the lack of transparency behind these decisions," said Reshma Ramachandran, an assistant professor and health services researcher at Yale School of Medicine. "The blanket removal of black-box warnings regarding risks of breast cancer and cardiovascular disease without clear justification can be misleading for patients and underplays real potential harms."

Ramachandran also pointed out that certain groups face particular risks, such as patients with histories of hormone-sensitive cancers. For these women, the removal of warnings could create confusion about the safety of menopause hormone treatments.

The Context: Menopause Patch Shortages

The FDA's announcement comes as patients across the US struggle with shortages of menopause patches. Officials highlighted these shortages during the briefing. "We are working with manufacturers to strengthen supply and improve access," said Dorothy Fink, deputy director of the National Institute of Child Health and Human Development.

While improving access is important, critics argue that removing safety warnings is not the right solution. The black-box warnings were originally added based on findings from the Women's Health Initiative, a large study that linked hormone therapy to increased risks of breast cancer, heart disease, and dementia.

However, more recent research has nuanced those findings, suggesting that the risks may vary depending on the type of hormone therapy, the age of the patient, and other factors. The FDA's decision to remove the warnings may reflect this evolving understanding, but without a public advisory committee review, the reasoning remains unclear.

What This Means for Patients

For women currently using menopause patches or considering hormone therapy, the removal of black-box warnings does not mean the risks have disappeared. It simply means the FDA no longer requires the most prominent warning on the label.

Patients should continue to discuss their individual risk factors with their healthcare providers. This is especially important for those with a history of breast cancer, heart disease, or stroke. The decision also underscores the need for clear communication between doctors and patients about the benefits and risks of MHT.

• Black-box warnings are the FDA's strongest safety alerts and are reserved for serious or life-threatening risks.
• The FDA removed these warnings from three more menopause patches without convening an advisory committee.
• Experts like Reshma Ramachandran criticize the lack of transparency and potential for misleading patients.
• Shortages of menopause patches are ongoing, and the FDA says it is working to strengthen supply.
• Patients should consult their doctors about individual risks, especially with a history of hormone-sensitive cancers.

Comparing the February and Latest Decisions

The February decision removed black-box warnings from six menopause treatments, and now three more patches have followed. Both actions were taken without public advisory committee meetings, which are typically used to review scientific evidence and provide recommendations.

The table highlights the pattern: the FDA has repeatedly bypassed its usual advisory process. This has led to questions about whether the agency is prioritizing access over safety, or whether it has unpublished data supporting the changes. The background to this story is set out in Menopause Hormone Therapy: Benefits, Risks & What to Know. A related thread runs through Menopause Hormone Therapy: Benefits, Risks, and What You Should K. Earlier coverage in Menopause Supplements Costing £400 a Year No Better Than £22 shows how the argument developed.

What to Watch Next

The FDA has not indicated whether it will release the scientific evidence behind these decisions. Advocates for patient safety are calling for more transparency. Meanwhile, the shortages of menopause patches continue, and the agency says it is working with manufacturers to improve supply. A closer look at the same subject appears in Antihistamines for PMDD and Menopause: What Experts Say. Anyone following the wider picture can start with Menopause Report Used Male Data: Why Clinical Trials Exclude Women. The same theme surfaces in New Career After 60: From Menopause Crisis to Standup Comedian, which takes a different angle.

For now, women using these patches should stay informed and speak with their healthcare providers about any concerns. The removal of a warning label does not change the underlying risks or benefits of hormone therapy, but it does change how that information is presented. Context on how this played out before sits in Judge Rules FDA Mifepristone Restrictions Arbitrary and.